PRIMA challenged Eirini with the following questions to tell a little bit more about the publication and the award.
- Congratulations on receiving the Jebsen Foundation's annual award for best publication! Can you tell us a bit about the publication that earned you this honor?
Thank you!! The publication focuses on an approach to treating acute myeloid leukemia (AML), a type of blood cancer. In this study, we engineered T cells to specifically target a common mutation in the FLT3 gene, which is often responsible for the growth of AML. By equipping T cells with a receptor that recognizes this mutation, we showed that these cells can effectively find and destroy AML cancer cells in the body. This targeted strategy shows potential for improving treatment outcomes for patients with AML.
- What was the inspiration behind your research, and what motivated you to pursue this particular topic?
The inspiration for this research came from the urgent need for better treatments for acute myeloid leukemia (AML). Despite progress in cancer therapies, AML is still a tough disease to treat, with a high chance of relapse and limited options. I was motivated by the fact that many AML patients have specific genetic mutations, like those in the FLT3 gene, that drive the disease. Ultimately, I believed we could use T cells, a part of the immune system, to target these mutations effectively.
- Can you describe some of the key findings or contributions of your publication?
Of course! Here are some key findings!
- Discovery of a T-cell receptor targeting a mutation in AML: We discovered a TCR that targets a mutation in FLT3 that is shared among AML patients
- Targeting the FLT3 Mutation: We engineered T cells with a receptor that specifically targets the FLT3 mutation found in AML patients.
- Elimination of Cancer Cells: We showed that these T cells can effectively kill primary human AML cells in living organisms, not just in lab tests.
- Minimal Side Effects: The T cells only attacked the cancer cells with the FLT3 mutation while leaving healthy cells unharmed, which is important for safety.
- Personalized Treatment: This study highlights the potential for developing personalized therapies for AML by targeting specific mutations, which could lead to better treatment options for patients.
- What challenges did you face during your research, and how did you overcome them?
Since this was a major part of my PhD, most of the challenges I faced were personal and closely related to my journey. One significant struggle was dealing with self-doubt, especially when experiments didn’t go as planned or when I struggled to understand complex ideas. This often led to anxiety about my progress and capabilities. To cope, I began sharing my feelings with friends and mentors, who provided much-needed encouragement and perspective.
Additionally, I experienced moments of isolation, especially during intense research periods and the long Norwegian winters. Being away from friends and family was tough, so I made a conscious effort to connect with others (even virtually). This helped lift my spirits and reminded me of the importance of having a support network.
Lastly, there were many times (especially as a PhD student) that I felt a lot of pressure to publish, which could be overwhelming at times. To manage this, I started setting small, manageable goals that helped me stay on track and reduced my stress.
- How do you feel about receiving this recognition from the Jebsen Foundation?
I’m extremely grateful to receive this recognition from the Jebsen Foundation. It means a lot to me and confirms that the effort I put into my research is appreciated. At the same time, this award is truly a shared achievement. It represents the commitment and hard work of our entire research team and our Swedish collaborators, Sten Eirik W. Jacobsen and Petter Woll, at the Karolinska Institute. Cancer research is, above all, a team effort, and I’m fortunate to work alongside such passionate colleagues. This recognition motivates us to keep moving forward and opens new doors for collaboration and breakthroughs that will ultimately benefit patients.
- With 20,000 NOK awarded for personal use, do you have any plans on how you might utilize this prize?
I honestly have not decided yet! But I am sure with Christmas approaching.... maybe treating myself to a little self-care or perhaps a short trip sounds good!
- You will also become a member of the Jebsen Academy. What opportunities do you think this membership will bring, and what are you looking forward to the most?
I believe it will offer excellent networking opportunities with other researchers, enabling me to share ideas and collaborate on future projects. I’m particularly looking forward to the biannual meetings, as they provide a wonderful chance to connect and learn about everyone’s current work.
Read the publication from the Olweus group.